Alnylam Shares Fall About 26% on Demand and Pipeline Concerns
Alnylam signaled slower-than-expected demand growth for AMVUTTRA and pushed back certain trial results, while citing near-term Medicare Advantage restrictions and proposed drug reimbursement pressures.
Shares of Alnylam Pharmaceuticals (ALNY) fell roughly 26% on Thursday after the company signaled slower-than-expected demand growth for its flagship AMVUTTRA therapy, pushed back certain trial results, and highlighted near-term pressures from Medicare Advantage restrictions and proposed drug reimbu…